checkAd
    Startseite > Aktien > Mesoblast > Nachrichten
    Mesoblast Aktie
    0,6700
     
    EUR
    +1,52 %
    +0,0100 EUR
    Letzter Kurs 03.05.24 Tradegate
    0,6500
     
    EUR
    3.095 STK
    Geldkurs 03.05.24
    0,6850
     
    EUR
    2.901 STK
    Briefkurs 03.05.24
    ISIN: AU000000MSB8 · WKN: A0DNPW · SYM: LWB · Australien

    Neueste Nachrichten

    Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
    30.04.24 · globenewswire · Mesoblast
    United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
    26.03.24 · globenewswire · Mesoblast
    Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
    14.03.24 · globenewswire · Mesoblast
    United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
    11.03.24 · globenewswire · Mesoblast
    Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
    28.02.24 · globenewswire · Mesoblast
    Mesoblast Financial Results and Corporate Update Webcast
    26.02.24 · globenewswire · Mesoblast
    United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor (Rexlemestrocel-L) in Children With Congenital Heart Disease
    15.02.24 · globenewswire · Mesoblast
    Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
    31.01.24 · globenewswire · Mesoblast
    United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor (Rexlemestrocel-L) in Children With Congenital Heart Disease
    19.01.24 · globenewswire · Mesoblast
    Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease
    27.11.23 · globenewswire · Mesoblast
    Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD
    22.11.23 · globenewswire · Mesoblast
    Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023
    31.10.23 · globenewswire · Mesoblast